Skip to contentB
BioMarin Pharmaceutical Inc
B
BMRNBioMarin Pharmaceutical Inc Source filing unavailable
Q4 2013 · —
derived · Computed from the longer spans the company filed.
Revenue$146.87M$146.87Mderived+11.3% vs Q4 2012 Net Income-$61.99M-$61.99MderivedN/M vs Q4 2012 EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$52,310,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioMarin Pharmaceutical Inc · CIK 1048477 · Engraved from SEC EDGAR
Operating Cash Flowderived-$11,296,000N/M Free Cash Flowderived-$41,049,000N/M Margins · derivedOperating margin-35.6%−0.1 pt vs Q4 2012
Net margin-42.2%−2.0 pt vs Q4 2012